Swiss Federal Institute of Technology, ETH Zürich, Institute of Food Nutrition and Health, Schorenstrasse 16, 8603 Schwerzenbach, Switzerland.
J Biol Chem. 2012 Feb 24;287(9):6421-30. doi: 10.1074/jbc.M111.310342. Epub 2011 Dec 29.
Increased nutrient intake leads to excessive adipose tissue accumulation, obesity, and the development of associated metabolic disorders. How the intestine signals to adipose tissue to adapt to increased nutrient intake, however, is still not completely understood. We show here, that the gut peptide GLP-1 or its long-lasting analog liraglutide, function as intestinally derived signals to induce adipocyte formation, both in vitro and in vivo. GLP-1 and liraglutide activate the GLP-1R, thereby promoting pre-adipocyte proliferation and inhibition of apoptosis. This is achieved at least partly through activation of ERK, PKC, and AKT signaling pathways. In contrast, loss of GLP-1R expression causes reduction in adipogenesis, through induction of apoptosis in pre-adipocytes, by inhibition of the above mentioned pathways. Because GLP-1 and liraglutide are used for the treatment of type 2 diabetes, these findings implicate GLP-1 as a regulator of adipogenesis, which could be an alternate pathway leading to improved lipid homeostasis and controlled downstream insulin signaling.
增加营养摄入会导致脂肪组织过度积累、肥胖和相关代谢紊乱的发生。然而,肠道如何向脂肪组织发出信号以适应增加的营养摄入,目前仍不完全清楚。我们在这里表明,肠肽 GLP-1 或其长效类似物利拉鲁肽可作为肠道来源的信号,在体外和体内诱导脂肪细胞形成。GLP-1 和利拉鲁肽激活 GLP-1R,从而促进前脂肪细胞增殖和抑制细胞凋亡。这至少部分是通过激活 ERK、PKC 和 AKT 信号通路来实现的。相比之下,GLP-1R 表达的缺失会通过抑制上述途径诱导前脂肪细胞凋亡,导致脂肪生成减少。由于 GLP-1 和利拉鲁肽被用于治疗 2 型糖尿病,这些发现表明 GLP-1 是脂肪生成的调节剂,这可能是一种改善脂质稳态和控制下游胰岛素信号的替代途径。